Kornimate/medical-research-clean huggingface dataset:
effect of probiotic on depression

Conditions: Depression

Summary: depressive disorder, also known as depression, is a type of mood disorder characterized by persistent low mood. the incidence of depression worldwide is about 6%. growing evidence suggested that the gut microbiota plays a key role in the development of depression. probiotics can effectively regulate gut microbiota, and showed potential in alleviating depression. this study investigated the effect of formula probiotic (containing lactobacillus paracasei, bifidobacterium animalis, bifidobacterium longum, bifidobacterium bifidum and lactobacillus plantarum) on depression.


Eligibility criteria:
inclusion criteria: * normal body mass index ≥ 18.5 until ≤ 29.9 * mild to moderate major depression diagnosed by psychiatrists according to the diagnostic criteria for depressive episodes in dsm-5 (american diagnostic and statistical manual of mental disorders (fifth edition)) * hamilton rating scale for depression (hamd-17) score not less than 8 * agreed to intake study product during the study period * agreed to sign written informed consent exclusion criteria: * use of systemic antibiotics or antimycotics medication in the 30 days prior to the study * investigator's uncertainty about the willingness or ability of subject to comply with the protocol requirements * persons with a milk protein allergy, lactose intolerance * pregnant or breastfeeding women * subject had other serious diseases
efficacy and safety of flamboyant 200/12 association in the treatment of adults with severe asthma

Conditions: Asthma

Summary: the purpose of this study is to evaluate the efficacy and safety of flamboyant 200/12 association in adults with asthma.


Eligibility criteria:
inclusion criteria: * ability to confirm voluntary participation and agree to all trial purposes by signing and dating the informed consent forms; * participants aged 18 years or more; * diagnosis of uncontrolled severe asthma; * participants with forced expiratory volume in 1 second (fev1) \> 60% of predicted; exclusion criteria: * any clinical and laboratory findings that, in the judgment of the investigator, may interfere with the safety of research participants; * known hypersensitivity to the formula components used during the clinical trial; * history of alcohol and/or substance abuse within 12 months prior to screening visit. * current smoking or smoking history equivalent to "10 pack years" * participants with untreated oral candidiasis; * pulmonary disease history (e.g., chronic obstructive pulmonary disease \[copd\], cystic fibrosis, bronchiectasis, tuberculosis); * participants with a history of acute asthma exacerbation, respiratory tract infection or hospitalization for asthma in the last 4 weeks; * known hiv-positive status or active hepatitis b or c virus test result * participants with current evidence or history of uncontrolled coronary artery disease, congestive heart failure, myocardial infarction or cardiac arrhythmia; * participants with a current medical history of cancer and/or cancer treatment in the last 5 years; * participants using medications that would have an effect on bronchospasm and / or lung function.

Keywords: asthma
rapid detection of bacterial resistance by maldi-tof ms and antibiotic savings

Conditions: Sepsis With Escherichia Coli

Summary: this study aims at determining within a short time (\<3h) the susceptibility to clinical isolates of e. coli to the major antibiotics directly from positive blood cultures.

the resistance to antibiotic is a concern for the great majority of pathogenic bacteria. the proportion of antibiotic-resistant bacteria is particularly high in hospital settings. the accumulation of resistance mechanisms can lead to multidrug resistance, therapeutic impasses and a subsequent higher mortality of infected patients. the use of antibiotics in humans and animals creates a selection pressure that favors the dissemination of antibiotic resistant strains. it's necessary to optimize antibiotic consumption to limit the spread of these bacteria. it requires both the fast bacterial identification and the fast determination of their resistance profile in order to use narrower-spectrum compounds. usually antibiotic susceptibility testing usually takes 18-24 hours. mass spectrometry type matrix-assisted laser desorption ionization time-of-flight (maldi-tof ms) has become a valuable tool in clinical laboratories for pathogen identification. preliminary data showed that susceptible and resistant bacteria can be differentiated within 1 or 2 hours with a new technology called 'ms-astra' based on a lower global peak intensity in the presence of the antibiotic of interest (at a concentration corresponding to the susceptibility breakpoint defined by the eucast) than in its absence. the objective of this study is to evaluate the performances of this new maldi-tof ms method on a panel of wild-type and resistant clinical isolates. this study aims to determine the resistance of escherichia coli isolates to cefotaxime, piperacillin-tazobactam, amoxicillin and to implement the method to positive blood cultures. minimal inhibitory concentrations will be determined the standard agar dilution method. results and full analyze are deliverable within 2 years. the data obtained with the ms-astra technique will be compared with the resistance status of the clinical isolates. the shortest incubation time (1 or 2 hours) that gives the more accurate result will be evaluate.the antibiotic savings that the implementation of this new method could have allowed will be evaluate.

Eligibility criteria:
inclusion criteria: * all patients hospitalized in the hospital of besançon, with a sepsis with e. coli. exclusion criteria: * patients without sepsis with e. coli

Keywords: antibiotic maldi-tof ms susceptibility testing
capnography in the post-anesthesia care unit (pacu)

Conditions: Obstructive Sleep Apnea; Bariatric Surgery Candidate; Respiratory Insufficiency

Summary: to understand if a progressive increase in end-tidal carbon dioxide (co2) levels are heralding respiratory difficulties before desaturation measured from capnography in obstructive sleep apnea patients, with the use of nasal prongs, transcutaneous monitors, capnostream, and massimo technologies.

background and significance carbon dioxide (co2) levels can be monitored throughout the respiratory cycle via capnography. in this way, capnography allows healthcare professionals to follow a number of respiratory factors (i.e., depression, apnea, and hypercapnia) in real-time. earlier detection of alterations to ventilation status will better enable providers to more accurately dose medications during procedures, especially in at-risk patient populations such as patients with obstructive sleep apnea (osa) \[1, 2\]. in a recent study of bariatric patients, approximately 15% experience postoperative pulmonary complications. these patients could benefit significantly from capnography monitoring as this measure can very accurately estimate the prevalence of respiratory complications. through this study we seek to understand how end-tidal co2 (etco2) levels of patients with obstructive sleep apnea vary when patients are in the post-anesthesia care unit (pacu). by collecting information on patient outcomes, we hope to better understand the value of this monitoring technique in an at-risk patient population. though capnography in the pacu has not previously been demonstrated to improve patient safety or satisfaction, capnography has never been studied in a population of patients who are at risk of obstructive sleep apnea. study design this is a prospective, blinded observational pilot study to monitor if changes in end-tidal co2 levels provide incremental value over pulse oximetry when detecting respiratory difficulties (i.e., hypercapnia).

Eligibility criteria:
inclusion criteria: * \> 18 years of age * patients who have are at tgh for bariatric surgery * bmi \> 30 * at risk of obstructive sleep apnea according to tgh stop-bang questionnaire exclusion criteria: * \<18 years of age * not at risk of obstructive sleep apnea according to tgh stop-bang questionnaire
osi-774 (tarceva) in treating patients with stage iii or stage iv non-small cell lung cancer

Conditions: Carcinoma, Non-small-cell Lung

Summary: the purpose of this study is to determine if osi-774 will improve overall survival of patients with incurable stage iiib/iv non-small cell lung cancer compared to standard of care. osi-774 is a new type of drug under evaluation called an epidermal growth factor receptor (egfr). osi-774 is an investigational drug that has not yet been approved by the u.s. food and drug administration (fda).


Eligibility criteria:
* clinical diagnosis of stage iiib or iv non-small cell lung cancer. * must have evidence of disease (clinical or radiological). * have failed 1 but no more than 2 prior chemotherapy regimens, have recovered from any side effects and have not had any chemotherapy for at least 21 days. * if the patient has had surgery, the surgery was at least 2 weeks ago. * patients whose cancer has spread to their brain or central nervous system are eligible, providing that they have been on stable dose of steroids for at least 4 weeks and are free of symptoms. * if the patient received radiation therapy, treatment was at least 4 weeks ago.

Keywords: non-small cell lung cancer tarceva egfr erlotinib
quality control of ce-certified phonak hearing aids - 2016_05

Conditions: Hearing Loss

Summary: a methodical evaluation of new ce-labelled phonak hearing systems is intended to be conducted on hard of hearing participants to grant quality control prior to product launch. the aim of the investigation series is to ensure zero-defect overall performance of the new hearing systems as well as maximum benefit for the participant with the devices in comparison to previously outstanding phonak hearing systems.

phonak hearing systems pass through different development and study stages. at an early stage, feasibility studies are conducted to investigate new algorithms, features and functions in an isolated manner. if the benefit is proven, their performance is then investigated regarding interdependency between all available algorithms, features and functions running in parallel in a hearing aid (pivotal/pre-validation studies) and, as a result, they get optimized. afterwards, and prior to product launch, the phonak hearing systems undergo a final quality control in terms of clinical trials in the way as planned for this study ("phase of final inspection"). this will be a controlled, single blinded and randomised active comparator clinical evaluation which will be conducted mono centric at sonova ag headquarters based in stäfa (switzerland).

Eligibility criteria:
inclusion criteria: * adult hearing impaired persons (minimum age: 18 years) with and without (experience with) hearing aids * good written and spoken (swiss) german language skills * healthy outer ear * ability to fill in a questionnaire (p/ecrf) conscientiously * informed consent as documented by signature exclusion criteria: * contraindications to the md in this study, e.g. known hypersensitivity or allergy to the investigational product * limited mobility and not in the position to attend weekly appointments in stäfa (switzerland) * limited ability to describe listening impressions/experiences and the use of the hearing aid * inability to produce a reliable hearing test result * massively limited dexterity * known psychological problems * central hearing disorders
the effect of gastric bypass on the pharmacokinetics of serotonin reuptake inhibitors

Conditions: Gastric Bypass; Depression; Anxiety Disorder

Summary: the morbidly obese frequently present with mood and anxiety disorders, which are often treated with serotonin reuptake inhibitors (sri) antidepressant drugs. the investigators hypothesized that gastric bypass surgery would decrease the absorption of sri. the investigators also wished to determine whether a reduction in sri levels would increase the likelihood of worsening depressive symptoms.

twelve rygb candidates who were successfully treated with an sri for primary mood or anxiety disorders were studied prospectively. blood samples for sri plasma levels were drawn immediately after dose for pharmacokinetic studies (pk) preoperatively. maximum concentration (cmax), time to cmax (tmax), and area under concentration/time curve (auc) were determined. pk studies were repeated at one, six, and twelve months post-operatively. pk data were corrected for dose at each study time point. the structured interview guide for the hamilton depression rating scale- atypical depression symptom version was used to quantify depressive symptoms.

Eligibility criteria:
inclusion criteria: * able to tolerate general anesthesia * able to document prior unsuccessful attempts at weight loss under medical supervision during the last 6 months * able to provide informed consent * cleared for surgery by primary care md, dietician, and psychiatrist * sri treatment specifically for depression for ≥6 wks at constant dose for last 2 out of 6 wks exclusion criteria: * pregnancy * unwilling or unable to comply with postoperative requirements for diet, supplements, exercise, or followup

Keywords: pharmacokinetics serotonin reuptake inhibitors gastric bypass depression bioavailability drug absorption area under curve
the differential pattern of deposition of nano particles in the airways of exposed workers

Conditions: Inadequate or Impaired Respiratory Function

Summary: investigation of the differences between the levels of extracellular and intracellular nano-particles in workers exposed to environmental particles during their employment to enhance understanding the process of penetration of the particles to respiratory epithelial cells.

this study investigates the following questions: does occupational exposure to nanoparticles influence permeation of such particles to respiratory airways? is there a correlation between the levels of nanoparticles in sample biological fluids of the patients and their pulmonary functions. is there a correlation between the levels of nanoparticles in sample biological fluids of the patients and respiratory tract infections. the study protocol includes the following steps: initial interview of the patient measurement of nanoparticles in samples of exhaled breath condensate using nanosight lm 20 measurement of nanoparticles in induced sputum. and finally examination of the relationship between the measured parameters and the indices of pulmonary infection, and pulmonary function as measured by the pulmonary department of the tasmc.

Eligibility criteria:
inclusion criteria: * adults over 20 years of age who visit ichilov hospital for medical complaints/inquiries regarding respiratory tract. * study population is composed of people who are exposed to environmental particles form industrial sources. * informed consent is requested from each subject. exclusion criteria: * unemployed individuals. * individuals who are not working in industrial jobs, such as office workers and secretaries.

Keywords: lung alveoli nanoparticles particulate matter exhaled breath condensate induced sputum forced expiratory volume force vital capacity
genotype and platelet reactivity in patients on hemodialysis

Conditions: Chronic Kidney Disease

Summary: patients with end stage renal disease (esrd) on hemodialysis (hd) exhibited higher platelet reactivity to clopidogrel than did those with normal renal function. we recently reported platelet inhibition by ticagrelor was faster and markedly greater than by clopidogrel with onset dosing regimen in patients with esrd on hd. however, few studies have been conducted genetic influence in high platelet reactivity in patients with esrd on hd.

chronic kidney disease (ckd) is a strong risk factor for cardiovascular morbidity and mortality, and confers an increasing risk of stent thrombosis even when dual antiplatelet therapy (clopidogrel and aspirin) is administered. patients with severe ckd or end stage renal disease (esrd) on hemodialysis (hd) exhibited higher platelet reactivity to clopidogrel than did those with normal renal function. we recently reported platelet inhibition by ticagrelor was markedly greater than by clopidogrel in patients with esrd on hd. but exact mechanism of high platelet reactivity in esrd patients was not fully evaluated. a possible postulation would be genetic influence. to investigate this issue, we will evaluate genetic polymorphism in patients with normal kidney function and esrd on hd according to different doses of clopidogrel and ticagrelor. genetic test will be assessed polymorphism of abcb1, pon1, cyp2c19, cyp2c9 and p2y12.

Eligibility criteria:
inclusion criteria: * esrd patients undergoing regular (≥ 6 months) maintenance hd * matching patients with normal kidney function * documented coronary artery disease or high risk (framingham heart risk score ≥ 20%) of coronary artery disease exclusion criteria: * known allergies to aspirin, clopidogrel, or ticagrelor * concomitant use of other antithrombotic drugs (oral anticoagulants, dipyridamole) * thrombocytopenia (platelet count \<100,000/mm3) * hematocrit \<25% * uncontrolled hyperglycemia (hemoglobin a1c \>10%) * liver disease (bilirubin level \>2 mg/dl) * symptomatic severe pulmonary disease * active bleeding or bleeding diathesis * gastrointestinal bleeding within the last 6 months * hemodynamic instability * acute coronary or cerebrovascular event within the last 3 months * pregnancy * any malignancy * concomitant use of a cytochrome p450 inhibitor or nonsteroidal anti-inflammatory drug * recent treatment (\<30 days) with a glycoprotein iib/iiia antagonist

Keywords: platelet ticagrelor clopidogrel end stage renal disease hemodialysis genetics
consistency of lge-mri fibrosis and eam low-voltage area

Conditions: Atrial Fibrillation

Summary: this study aims to: 1. assess the consistency of lge-mri bi-atrial fibrosis and electroanatomical mapping of bi-atrial low voltage region 2. to evaluate the electroanatomical characteristics of different types of fibrosis (dense fibrosis, patchy fibrosis, etc.) in different locations of the left and right atrium; 3. to explore the correlation between preoperative and postoperative bi-atrial fibrosis and long-term recurrence in patients with atrial fibrillation.


Eligibility criteria:
inclusion criteria: 1. adult patients (≥18 years old) who are willing to participate in this study and can sign informed consent; 2. atrial fibrillation was diagnosed and catheter ablation was proposed exclusion criteria: 1. left atrial thrombus or left atrial appendage thrombus; 2. severe chronic obstructive pulmonary disease (fev1/ fvc\<70%, fev1\<50% predicted value); 3. absolute contraindications of anticoagulation therapy; 4. currently pregnant; 5. contraindications for lge-mri (claustrophobia, pacemaker implantation, egfr\<30ml/min for renal insufficiency, severe obesity, pregnancy, gadolinium chelating agent allergy, etc.); 6. refuse to participate in the study; 7. other physical or mental incapacity to participate in the study.
study to investigate the clinical benefits of dietary supplement quercetin for managing early mild symptoms of covid-19

Conditions: COVID-19

Summary: quercetin is a flavonoid dietary supplement that occurs in many edible fruits and vegetables. it has remarkable antioxidant, anti-inflammatory, immunoprotective and antiviral properties. it is widely used to boost the body immune system against infections and keeping healthy life-style. the purpose of the present study is to investigate the potential benefits of quercetin for preventing covid-19 disease progression and symptoms improvement in the early stage of infection.

the strong antioxidant and anti-inflammatory properties of quercetin are closely related to its effective fight against a variety of disease conditions related to inflammation, including: viral infections, allergies, asthma, hay fever, arthritis, respiratory diseases, "hardening of the arteries" (atherosclerosis), high cholesterol, heart disease and circulation problems, insulin resistance and diabetes, eye-related disorders, including cataracts, stomach ulcers, cognitive impairment, gout, cancer, chronic fatigue syndrome, inflammation of the prostate, bladder, and ovaries, chronic infections of the prostate, skin disorders, including dermatitis and hives. quercetin can help stop damaging particles in the body known as free radicals, which damages the cells by natural oxidation processes. it can also reduce the expression of inflammatory genes in the cells. quercetin has been shown to be effective against broad range of viruses including human respiratory syncytial virus (hrsv), rhinovirus, echovirus, coxsackievirus, poliovirus, parainfluenza type 3, herpes simplex virus-1, cytomegalovirus, sars-cov-1, dengue virus, and hepatitis c virus. the purpose of the present study is to investigate the potential benefits of quercetin for preventing covid-19 disease progression and improving symptoms in the early stage of infection.

Eligibility criteria:
inclusion criteria: * patients must be 18 years of age or older, of either gender * patients must be tested positive for sars-cov-2 by rt-pcr * patients must exhibit typical symptoms of covid-19 disease at screening such as fever, fatigue, a dry and contagious cough, loss of appetite, body aches, shortness of breath, mucus or phlegm, sore throat, headache, chills, sometimes with shaking, loss of smell or taste, congestion or runny nose, nausea, or vomiting, diarrhea, muscular pain etc. * patients must be in the early stage of covid-19 disease who do not require hospitalisation at the time of screening * patients must be under the care of a physician for diagnosis of covid-19 * patients who have signed informed consent exclusion criteria: * patients with proven hypersensitivity or allergic reaction to quercetin * patients with known chronic kidney disease with estimated creatinine clearance \< 50 ml/minute or need for dialysis * patients who are severely hypotensive defined as needing hemodynamic pressors to maintain blood pressure * patients with moderate or severe thrombocytopenia (platelet count \<100 × 10⁹/l); * pregnant patients * patients declining to participate